PLANTATION, Fla., Feb. 28 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) today announced that the Company is scheduled to make a
presentation at BioSquare 2006, a premier European biotechnology partnering
conference, to be held in Geneva, Switzerland during March 8-10.
Presentation details are as follows:
* Event: BioSquare 2006
Presenter: Charles A. Rice, President & CEO
When: Thursday, March 9, 2006 at 11:15 a.m.
Where: Level 2, Room 7
Mr. Rice will discuss the Company's recent Swedish approval of
Multiferon(R) (multi-subtype, natural human alpha interferon) for the first-
line adjuvant treatment of high-risk (Stages IIb-III) malignant melanoma
following dacarbazine (DTIC) after surgical removal of tumors.
"We have now launched our Multiferon(R) marketing program for melanoma in
Sweden, and we expect sales to contribute to revenue growth in the coming
months," stated Mr. Rice. "We will be working with regulatory authorities in
the following weeks to implement our strategy for the European Union. In
addition, plans are underway for our post-marketing clinical trial in melanoma
with the next immediate steps being the selection of a Clinical Research
Organization (CRO) and identification of investigational sites. We are also
considering the inclusion of sites outside of the EU, in order to both support
our international licensees and gain access to additional sources of
patients."
In addition, Mr. Rice will present on progress related to the OVA(TM)
System and its humanized antibody programs targeting solid tumors.
In other news, the Company reported that it believes that a pending
financing transaction will secure an immediate source of new working capital.
Complete details are expected to be announced shortly.
About Viragen, Inc.:
With global operations in the U.S., Scotland and Sweden, Viragen is a
biotechnology company engaged in the research, development, manufacture and
commercialization of pharmaceutical proteins for the treatment of viral
diseases and cancers. Our product portfolio includes: Multiferon(R) (multi-
subtype, natural human alpha interferon) targeting a broad range of infectious
and malignant diseases; and humanized monoclonal antibodies targeting specific
antigens over-expressed on many types of cancers. We are also pioneering the
development of Avian Transgenic Technology, with the renowned Roslin
Institute, as a revolutionary manufacturing platform for the large-scale,
efficient and economical production of human therapeutic proteins and
antibodies.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expects," "potential,"
"suggests," "may," "should," "could," or similar expressions. Such forward-
looking statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
http://www.newscom.com/cgi-bin/prnh/20060221/FLTU004
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
